Trial reportNutrients2026
Effects of Heat-Killed
Trial report in Nutrients, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
BACKGROUND/
objectivesSkin aging is a multifactorial process driven by intrinsic and extrinsic factors. Orally administered postbiotics may support skin homeostasis; however, clinical validation of their efficacy remains limited. In this study, we aimed to examine the effect of oral supplementation with the heat-killed lactic acid bacterium
methodsIn this 12-week, randomized, double-blind, placebo-controlled trial, 100 participants were assigned to receive either ID-ACT 3302 or a placebo. The prespecified primary endpoint was the change in crow's-feet wrinkles at week 12, assessed using investigator visual wrinkle grading and PRIMOS
resultsIn the full analysis set, wrinkle grade, hydration, TEWL, and elasticity improved over 12 weeks in both groups; however, ID-ACT 3302 exhibited no superiority over placebo for the primary wrinkle endpoints. The overall elasticity index R2 exhibited significant inter-group difference, whereas R5, R7, hydration, TEWL, and global assessment scores improved consistently in both groups. In the absence of multiplicity adjustments for secondary endpoints, the R2 finding is considered exploratory. Safety outcomes were comparable between the groups, with no serious adverse events.
conclusionsThe 12-week supplementation with ID-ACT 3302 was safe and well tolerated. However, no placebo-adjusted benefit was observed for the prespecified primary wrinkle endpoints. An exploratory between-group difference was observed for the Cutometer overall elasticity index (R2), but because secondary endpoints were not multiplicity-adjusted and the effect size was small, this finding should be interpreted as hypothesis-generating and requires confirmation in adequately powered trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.